In meta-analyses, the occurrence of enterocolitis as an irAE with CPI therapies is shown to be mainly dependent on the type of therapy (more frequent with CTLA-4 antibodies than with PD-1 antibodies) (56), while the localization and the entity of the tumor do not seem to influence the probability. This evidence concerns the gene CTLA4 and enterocolitis.